Mineralys Therapeutics, Inc. announced that it will present data from its Phase 2 Advance-HTN trial on lorundrostat, a novel aldosterone synthase inhibitor for treating uncontrolled and resistant ...

Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with ...

CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.

Mineralys Therapeutics, Inc. has announced the publication of detailed results from its pivotal Phase 2 Advance-HTN trial in the New England Journal of Medicine. The study assessed lorundrostat, an ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), ...